World's Best Scientists 2026 revealed!
Jürgen K. Rockstroh

Jürgen K. Rockstroh

D-Index & Metrics

Immunology

D-Index
95
Citations
34988
World Ranking
893
National Ranking
55

Medicine

D-Index
95
Citations
35018
World Ranking
10023
National Ranking
549

Jürgen K. Rockstroh publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Jürgen K. Rockstroh sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 575 publications — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Jürgen K. Rockstroh D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Jürgen K. Rockstroh sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 95 D-Index — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Jürgen K. Rockstroh is affiliated with the University Hospital Bonn in Germany and has an extensive research portfolio primarily focused on medicine. Their work spans several subfields including infectious diseases, epidemiology, hepatology, emergency medicine, and virology. The scientist's contributions include a significant body of research on topics such as hepatitis C virus research, HIV/AIDS drug development and treatment, HIV/AIDS research and interventions, liver disease diagnosis and treatment, HIV-related health complications and treatments, HIV research and treatment, and hepatitis B virus studies.

Rockstroh has authored numerous papers, with notable publications including:

  • 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0, 2020, HIV Medicine
  • Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV, 2021, Nature Communications
  • Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023, 2023, HIV Medicine
  • Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials, 2021, Clinical Infectious Diseases
  • Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus, 2020, Clinical Infectious Diseases

The publication venues where Rockstroh frequently appears include HIV Medicine, Clinical Infectious Diseases, Infection, SSRN Electronic Journal, and The Journal of Infectious Diseases. The distribution of publications is strongest in HIV Medicine, followed by Clinical Infectious Diseases and Infection.

In terms of collaborative work, Rockstroh has coauthored extensively with several researchers, with the most frequent collaborators being Christoph Boesecke, Christoph Stephan, Kathrin van Bremen, Sanjay Bhagani, and Andri Rauch. These collaborations suggest a network focused on infectious and chronic diseases related to HIV and hepatitis.

Best Publications

  • Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

    Francesca J. Torriani;Maribel Rodriguez-Torres;Jürgen K. Rockstroh;Eduardo Lissen

  • Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

    Alison J Rodger;Valentina Cambiano;Tina Bruun;Pietro Vernazza

  • Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

    Roy T. Steigbigel;David A. Cooper;Princy N. Kumar;Joseph E. Eron

  • Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans

    U Salzer;H M Chapel;A D B Webster;Q Pan-Hammarström

  • Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

    Paul E. Sax;Kristine M. Erlandson;Jordan E. Lake;Grace A. McComsey

  • Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

    Gerd Fätkenheuer;Anton L Pozniak;Margaret A Johnson;Andreas Plettenberg

  • Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.

    Naztfa Qurishi;Christina Kreuzberg;Guido Lüchters;Wolfgang Effenberger

  • Late presentation of HIV infection: a consensus definition

    A Antinori;T Coenen;D Costagiola;N Dedes

  • Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

    David A. Cooper;Roy T. Steigbigel;Jose M. Gatell;Jurgen K. Rockstroh

  • Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission

    Linda Gail Bekker;Linda Gail Bekker;George Alleyne;Stefan Baral;Javier Cepeda

  • Influence of Hepatitis C Virus Infection on HIV-1 Disease Progression and Response to Highly Active Antiretroviral Therapy

    Jiirgen K. Rockstroh;Amanda Mocroft;Vincent Soriano;Cristina Tural

  • Beyond viral suppression of HIV – the new quality of life frontier

    Jeffrey V. Lazarus;Jeffrey V. Lazarus;Kelly Safreed-Harmon;Simon E. Barton;Dominique Costagliola

  • Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection.

    Marcus Altfeld;Marylyn M. Addo;Eric S. Rosenberg;Frederick M. Hecht

  • Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

    Edwin DeJesus;Jürgen K. Rockstroh;Keith Henry;Jean Michel Molina

  • Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.

    Vincent Soriano;Mark Sulkowski;Colm Bergin;Angelos Hatzakis

  • Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    Unknown

  • Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

    Joel Gallant;Adriano Lazzarin;Anthony Mills;Chloe Orkin

  • Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men

    Thijis van de Laar;Oliver Pybus;Sylvia Bruisten;David Brown

  • Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): A non-randomised, open-label trial

    Jürgen K. Rockstroh;Mark Nelson;Christine Katlama;Jay Lalezari

  • Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

    Jan van Lunzen;Franco Maggiolo;José R Arribas;Aza Rakhmanova

  • The way forward in HCV treatment — finding the right path

    Michael P. Manns;Graham R. Foster;Jürgen K. Rockstroh;Stefan Zeuzem

  • Selective Escape from CD8+ T-Cell Responses Represents a Major Driving Force of Human Immunodeficiency Virus Type 1 (HIV-1) Sequence Diversity and Reveals Constraints on HIV-1 Evolution

    Todd M. Allen;Marcus Altfeld;Shaun C. Geer;Elizabeth T. Kalife

Frequent Co-Authors

Ulrich Spengler
Ulrich Spengler University of Bonn
Tilman Sauerbruch
Tilman Sauerbruch University of Bonn
Jens D. Lundgren
Jens D. Lundgren Rigshospitalet
Amanda Mocroft
Amanda Mocroft University College London
Gerd Fätkenheuer
Gerd Fätkenheuer University of Cologne
Vincent Soriano
Vincent Soriano Universidad Internacional De La Rioja
Jacob Nattermann
Jacob Nattermann University Hospital Bonn
Stefan Mauss
Stefan Mauss Université Paris Cité
Rolf Kaiser
Rolf Kaiser University of Cologne
Thomas A. Lutz
Thomas A. Lutz University of Zurich

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Immunology often links to broader healthcare professions, especially nursing and advanced practice roles. Many students explore accelerated paths, including accelerated nurse practitioner programs, which offer a fast track to becoming a Nurse Practitioner (NP). These programs are ideal for those who want to quickly transition from foundational nursing knowledge to specialized care roles.

For nurses interested in expanding their scope, transitioning from FNP (Family Nurse Practitioner) to acute care roles is common. Detailed guidance on how to make this shift is well-covered in resources about fnp to acnp pathways, highlighting additional certifications and clinical experience needed.

Starting a nursing career without a prior nursing background is also feasible through online RN programs for non nurses. These programs equip students with essential nursing skills and credentials to enter the healthcare workforce confidently.

Moreover, understanding compensation trends can help align career goals. For example, those pursuing advanced roles such as a Doctor of Nursing Practice (DNP) should review dnp salary data to evaluate potential earnings based on location and specialization.

Best Scientists Citing Jürgen K. Rockstroh

Trending Scientists

Recently Published Articles